Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000

(MarketWatch)

The so called 'living drug' Tisagenlecleucel (aka Kymriah™ by Novartis) is a new CAR-T cell therapy = Docs say pricy gene-altering will violently attack, avert, and might cure harsh B-cell leukaemias

Anagram: Julian Lofts
Image: Novartis AG